UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
May 11, 2015
________________
 
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 
 
Novo Nordisk A/S – Share repurchase programme
 
 
Bagsværd, Denmark, 11 May 2015 – On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK
17.5 billion to be executed during a 12-month period beginning 30 January 2015.
 
Under the programme initiated 30 April 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 9.3 billion in the period from 30 April 2015 to 27 October 2015.
 
Since the announcement as of 30 April 2015, the following transactions have been made under the programme:
 
  
 
 
Number of
B shares
 
 
Average
purchase price
 
Transaction
value, DKK
Accumulated, last announcement
-
 
-
30 April 2015
200,000
378.56
75,711,040
4 May 2015
195,000
383.03
74,690,909
5 May 2015
215,000
377.06
81,067,943
6 May 2015
210,000
368.55
77,394,555
7 May 2015
200,000
367.21
73,442,840
8 May 2015
200,000
371.39
74,278,300
       
Accumulated under the programme
1,220,000
 
456,585,587
 
 
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 18,430 B shares in the period from 30 April 2015 to 8 May 2015. The shares in these transactions were not part of the Safe Harbour repurchase programme.
 
 
 
 
Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 21,018,326 B shares of DKK 0.20, corresponding to 0.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.
 
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 8 May 2015, Novo Nordisk has repurchased a total of 12,397,904 B shares equal to a transaction value of DKK 4,156,585,257.
 
 
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,  Facebook, Twitter, LinkedIn, YouTube
 
  
Further information
Media:    
Anne Margrethe Hauge
+45 3079 3450
amhg@novonordisk.com
 
 
 
Investors:    
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com
 
 
 
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
 
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
       
   
Company announcement No 32 / 2015
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: May 11, 2015
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
Chief Executive Officer
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novo Nordisk Charts.